Aging is a gradual and irreversible pathophysiological process. It presents with declines in
tissue and cell functions and significant increases in the risks of various aging-related …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label,
proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and …

Background and Objectives To evaluate brain volume changes caused by different
subclasses of anti–β-amyloid (Aβ) drugs trailed in patients with Alzheimer disease. Methods …

Alzheimer's disease (AD) remains one of the grand challenges facing human society. Much
controversy exists around the complex and multifaceted pathogenesis of this prevalent …

Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

In Alzheimer's disease (AD), Aβ deposits form slowly, several decades before further
pathological events trigger neurodegeneration and dementia. However, a substantial …

Background Recent clinical and experimental studies have highlighted the involvement of
Ventral Tegmental Area (VTA) dopamine (DA) neurons for the early pathogenesis of …

Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported
both detrimental and protective effects of microglia on AD progression. Here, we used CSF …